trending Market Intelligence /marketintelligence/en/news-insights/trending/ixqzlesyfb-4jtesytqzgw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Achillion Pharmaceuticals appoints former uniQure exec as COO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Achillion Pharmaceuticals appoints former uniQure exec as COO

Achillion Pharmaceuticals Inc. named Paul Firuta to the positions of executive vice president and COO, effective Sept. 10.

Firuta most recently served as the chief commercial officer of uniQure NV, an Amsterdam-based gene-editing company.

Prior to joining uniQure, Firuta was the president of U.S. commercial operations in Bedminster, N.J.-based NPS Pharmaceuticals Inc., a biopharmaceutical company that develops treatments for gastrointestinal and endocrine disorders.

New Haven, Conn.-based Achillion Pharmaceuticals is focused on developing its oral factor D inhibitors to treat rare diseases with no or inadequate approved therapies.